Correlation Between CytomX Therapeutics and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both CytomX Therapeutics and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CytomX Therapeutics and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between CytomX Therapeutics and Inhibikase Therapeutics, you can compare the effects of market volatilities on CytomX Therapeutics and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CytomX Therapeutics with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of CytomX Therapeutics and Inhibikase Therapeutics.
Diversification Opportunities for CytomX Therapeutics and Inhibikase Therapeutics
-0.69 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between CytomX and Inhibikase is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding CytomX Therapeutics and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and CytomX Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CytomX Therapeutics are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of CytomX Therapeutics i.e., CytomX Therapeutics and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between CytomX Therapeutics and Inhibikase Therapeutics
Given the investment horizon of 90 days CytomX Therapeutics is expected to generate 0.65 times more return on investment than Inhibikase Therapeutics. However, CytomX Therapeutics is 1.55 times less risky than Inhibikase Therapeutics. It trades about -0.04 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about -0.08 per unit of risk. If you would invest 101.00 in CytomX Therapeutics on August 28, 2024 and sell it today you would lose (5.00) from holding CytomX Therapeutics or give up 4.95% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
CytomX Therapeutics vs. Inhibikase Therapeutics
Performance |
| Timeline |
| CytomX Therapeutics |
| Inhibikase Therapeutics |
CytomX Therapeutics and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with CytomX Therapeutics and Inhibikase Therapeutics
The main advantage of trading using opposite CytomX Therapeutics and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CytomX Therapeutics position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| CytomX Therapeutics vs. Eliem Therapeutics | CytomX Therapeutics vs. Scpharmaceuticals | CytomX Therapeutics vs. Milestone Pharmaceuticals | CytomX Therapeutics vs. Seres Therapeutics |
| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |